Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 197-202

  Straka, Robert J ^a   Burkhardt, R Todd ^a   Fisher, James E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Fenofibrate; Fenofibric acid; HPLC; Nonsteroidal anti inflammatory drugs; Serum

Indexed keywords

1 NAPHTHYLACETIC ACID; CLOFIBRIC ACID; FENOFIBRIC ACID;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; STEADY STATE;

ANION EXCHANGE RESINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; PROCETOFEN; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

EID: 34248219427     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/ftd.0b013e318030860a     Document Type: Article

References (18)

1. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
2. Tricor (fenofibrate tablets) package insert. North Chicago, IL: Abbott, 2001.
3. Goldberg AC, Schonfeld G, Feldman EB, et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther. 1989;11:69-83.
4. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis. 1986;6:670-678.
5. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptoralpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245-257.
6. Marz W, Schmitz H, Back G, et al. Micronised fenofibrate: efficacy and tolerability in the treatment of isolated and combined dyslipidemia [in German]. Munch Med Wschr. 1994;136:50-58.
7. Straka RJ, Burkhardt RT, Li N, et al. Fenofibric acid exposure and determinants of triglyceride response from NHLBI sponsored Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study. Clin Pharmacol Therapeutics. 2006;79:P37.
8. Masnatta LD, Cuniberti LA, Rey RH, et al. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;687:437-442.
9. Lossner A, Banditt P, Troger U. Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography. Pharmazie. 2001;56:50-51.
10. Streel B, Hubert P, Ceccato A. Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;742:391-400.
11. Kroll MH, Praestgaard J, Michaliszyn E, et al. Evaluation of the extent of nonlinearity in reportable range studies. Arch Pathol Lab Med. 2000;124:1331-1338.
12. Jhang JS, Chang CC, Fink DJ, et al. Evaluation of linearity in the clinical laboratory. Arch Pathol Lab Med. 2004;128:44-48.
13. National Committee for Clinical Laboratory Standards. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach. Approved Guideline. National Committee for Clinical Laboratory Standards document EP6-A ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003.
14. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem. 1974;20:1255-1270.
15. Guidance for Industry: Bioanalytical Method Validation. U.S. Food and Drug Administration Center for Drug Evaluation and Research, 2001.
16. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990;40:260-290.
17. Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm. 1978;16:570-574.
18. Urien S, Albengres E, Zini R, et al. Serum binding and interactions of chlorophenoxyisobutyric acid, itanoxone and fenofibric acid according to their different HSA binding sites. In: Fumagalli R, Kritchevsky D, Paoletti R, eds. Drugs Affecting Lipid Metabolism: Proceedings of the VIIth International Symposium on Drugs Affecting Lipid Metabolism, held in Milan, Italy, 28 to 31 May 1980. Symposia of the Giovanni Lorenzini Foundation. Vol. 7. Amsterdam, New York: Elsevier/North-Holland Biomedical Press; 1980:201-209.